Lite Strategy (LITS) Competitors

$1.23 -0.02 (-1.21%)

As of 01:51 PM Eastern

LITS vs. ORMP, TNYA, BDTX, CRDL, and HURA

Should you be buying Lite Strategy stock or one of its competitors? The main competitors of Lite Strategy include Oramed Pharmaceuticals (ORMP), Tenaya Therapeutics (TNYA), Black Diamond Therapeutics (BDTX), Cardiol Therapeutics (CRDL), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Lite Strategy compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Oramed Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Oramed Pharmaceuticals and Oramed Pharmaceuticals both had 1 articles in the media. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat Lite Strategy's score of 1.87 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Very Positive
Lite Strategy	Very Positive

Oramed Pharmaceuticals' return on equity of -6.83% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%
Lite Strategy	N/A	-68.86%	-67.48%

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of Lite Strategy shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Lite Strategy shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals has higher earnings, but lower revenue than Lite Strategy. Lite Strategy is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	89.21	$64.05M	$1.49	2.96
Lite Strategy	$65.30M	0.68	-$15.94M	-$1.33	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Oramed Pharmaceuticals beats Lite Strategy on 10 of the 12 factors compared between the two stocks.

How does Lite Strategy compare to Tenaya Therapeutics?

Lite Strategy (NASDAQ:LITS) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Lite Strategy has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the broader market.

Lite Strategy's return on equity of -68.86% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-68.86%	-67.48%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Lite Strategy has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.68	-$15.94M	-$1.33	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 298.01%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by company insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Tenaya Therapeutics had 7 more articles in the media than Lite Strategy. MarketBeat recorded 8 mentions for Tenaya Therapeutics and 1 mentions for Lite Strategy. Lite Strategy's average media sentiment score of 1.87 beat Tenaya Therapeutics' score of 0.53 indicating that Lite Strategy is being referred to more favorably in the media.

Company	Overall Sentiment
Lite Strategy	Very Positive
Tenaya Therapeutics	Positive

Summary

Tenaya Therapeutics beats Lite Strategy on 10 of the 15 factors compared between the two stocks.

How does Lite Strategy compare to Black Diamond Therapeutics?

Lite Strategy (NASDAQ:LITS) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Lite Strategy has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.34, suggesting that its share price is 234% more volatile than the broader market.

Black Diamond Therapeutics' return on equity of -30.18% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-68.86%	-67.48%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

Black Diamond Therapeutics has higher revenue and earnings than Lite Strategy. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.68	-$15.94M	-$1.33	N/A
Black Diamond Therapeutics	$70M	2.28	$22.37M	-$0.77	N/A

Black Diamond Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 258.94%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Black Diamond Therapeutics had 10 more articles in the media than Lite Strategy. MarketBeat recorded 11 mentions for Black Diamond Therapeutics and 1 mentions for Lite Strategy. Lite Strategy's average media sentiment score of 1.87 beat Black Diamond Therapeutics' score of 1.34 indicating that Lite Strategy is being referred to more favorably in the media.

Company	Overall Sentiment
Lite Strategy	Very Positive
Black Diamond Therapeutics	Positive

Summary

Black Diamond Therapeutics beats Lite Strategy on 14 of the 16 factors compared between the two stocks.

How does Lite Strategy compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, Cardiol Therapeutics had 4 more articles in the media than Lite Strategy. MarketBeat recorded 5 mentions for Cardiol Therapeutics and 1 mentions for Lite Strategy. Lite Strategy's average media sentiment score of 1.87 beat Cardiol Therapeutics' score of 0.57 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Positive
Lite Strategy	Very Positive

Cardiol Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 541.51%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardiol Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 1.6% of Lite Strategy shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lite Strategy has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Lite Strategy	$65.30M	0.68	-$15.94M	-$1.33	N/A

Lite Strategy's return on equity of -68.86% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-239.10%	-165.77%
Lite Strategy	N/A	-68.86%	-67.48%

Summary

Cardiol Therapeutics and Lite Strategy tied by winning 7 of the 14 factors compared between the two stocks.

How does Lite Strategy compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, TuHURA Biosciences had 4 more articles in the media than Lite Strategy. MarketBeat recorded 5 mentions for TuHURA Biosciences and 1 mentions for Lite Strategy. Lite Strategy's average media sentiment score of 1.87 beat TuHURA Biosciences' score of 0.81 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
TuHURA Biosciences	Positive
Lite Strategy	Very Positive

TuHURA Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 275.78%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 1.6% of Lite Strategy shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lite Strategy has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.63	N/A
Lite Strategy	$65.30M	0.68	-$15.94M	-$1.33	N/A

Lite Strategy's return on equity of -68.86% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-182.40%	-117.49%
Lite Strategy	N/A	-68.86%	-67.48%

Summary

Lite Strategy beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

Get Lite Strategy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LITS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LITS vs. The Competition

Export

Metric	Lite Strategy	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$44.00M	$895.11M	$4.24B	$12.04B
Dividend Yield	N/A	4.84%	5.78%	5.23%
P/E Ratio	-0.91	1.58	23.46	25.22
Price / Sales	0.68	117.93	148.88	74.60
Price / Cash	0.20	20.07	49.53	36.29
Price / Book	0.25	7.61	35.77	6.58
Net Income	-$15.94M	-$3.77M	$114.78M	$333.40M
7 Day Performance	7.46%	57.01%	0.04%	-0.99%
1 Month Performance	5.60%	49.06%	4.05%	7.15%
1 Year Performance	N/A	104.73%	19.83%	34.19%

Lite Strategy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LITS Lite Strategy	0.6658 of 5 stars	$1.23 -1.2%	N/A	N/A	$44.00M	$65.30M	N/A	100	Positive News
ORMP Oramed Pharmaceuticals	2.2754 of 5 stars	$4.01 +0.8%	N/A	+105.3%	$161.72M	$2M	2.68	10	Positive News
TNYA Tenaya Therapeutics	2.9471 of 5 stars	$0.74 +4.1%	$4.00 +444.2%	+141.1%	$159.71M	N/A	N/A	110	Earnings Report Upcoming Earnings Analyst Upgrade
BDTX Black Diamond Therapeutics	3.6534 of 5 stars	$2.65 +1.9%	$10.00 +277.4%	+79.3%	$151.59M	$70M	7.15	90	Positive News Earnings Report Analyst Downgrade Analyst Revision
CRDL Cardiol Therapeutics	2.5691 of 5 stars	$1.35 -1.8%	$8.50 +532.0%	+16.1%	$150.40M	N/A	N/A	20	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LITS) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lite Strategy (LITS) Competitors

LITS vs. ORMP, TNYA, BDTX, CRDL, and HURA

How does Lite Strategy compare to Oramed Pharmaceuticals?

Summary

How does Lite Strategy compare to Tenaya Therapeutics?

Summary

How does Lite Strategy compare to Black Diamond Therapeutics?

Summary

How does Lite Strategy compare to Cardiol Therapeutics?

Summary

How does Lite Strategy compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS vs. The Competition

Lite Strategy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lite Strategy (LITS) Competitors

LITS vs. ORMP, TNYA, BDTX, CRDL, and HURA

How does Lite Strategy compare to Oramed Pharmaceuticals?

Which has more risk & volatility, ORMP or LITS?

Does the media prefer ORMP or LITS?

Is ORMP or LITS more profitable?

Do institutionals & insiders have more ownership in ORMP or LITS?

Which has stronger valuation and earnings, ORMP or LITS?

Do analysts rate ORMP or LITS?

Summary

How does Lite Strategy compare to Tenaya Therapeutics?

Which has more volatility & risk, LITS or TNYA?

Is LITS or TNYA more profitable?

Which has preferable earnings & valuation, LITS or TNYA?

Do analysts prefer LITS or TNYA?

Do insiders and institutionals hold more shares of LITS or TNYA?

Does the media favor LITS or TNYA?

Summary

How does Lite Strategy compare to Black Diamond Therapeutics?

Which has more volatility & risk, LITS or BDTX?

Is LITS or BDTX more profitable?

Which has preferable earnings & valuation, LITS or BDTX?

Do analysts prefer LITS or BDTX?

Do insiders and institutionals hold more shares of LITS or BDTX?

Does the media favor LITS or BDTX?

Summary

How does Lite Strategy compare to Cardiol Therapeutics?

Does the media refer more to CRDL or LITS?

Do analysts prefer CRDL or LITS?

Which has more volatility and risk, CRDL or LITS?

Do institutionals and insiders hold more shares of CRDL or LITS?

Which has better earnings and valuation, CRDL or LITS?

Is CRDL or LITS more profitable?

Summary

How does Lite Strategy compare to TuHURA Biosciences?

Does the media refer more to HURA or LITS?

Do analysts prefer HURA or LITS?

Which has more volatility and risk, HURA or LITS?

Do institutionals and insiders hold more shares of HURA or LITS?

Which has better earnings and valuation, HURA or LITS?

Is HURA or LITS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS vs. The Competition

Lite Strategy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools